Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Govt Unveils Draft Honebuto Paper for 2021, Cabinet OK Expected after Party Tweaks
June 10, 2021
- Japan PM Vows to Vaccinate All People by October-November
June 10, 2021
- LDP Panel Urges 500 Billion Yen Support over 10 Years for Japan-Made Jabs
June 9, 2021
- Japan Aims for 80% Generic Share in All Prefectures by FY2023-End: Honebuto Draft
June 9, 2021
- 33 New Products Including Celecoxib Added to 18th Edition of Japanese Pharmacopoeia
June 8, 2021
- G7 Health Ministers Adopt Declaration Aimed at Greater Cooperation to Expedite Drug, Vaccine Development
June 8, 2021
- Label Revision Ordered for Clozaril to Increase Blood Testing Interval, Relaxed Re-Administration Criteria
June 4, 2021
- MHLW Mulls Sakigake System for SaMD with Medical Device as a Model: Official
June 3, 2021
- LDP Group on Generics Calls for Sustainable Supply Scheme: Proposal
June 3, 2021
- Japan to Establish Ecosystem to Deliver Innovative Drugs: Draft Growth Strategy
June 3, 2021
- Deregulation Panel Prods Govt to Fuel SaMD Development
June 3, 2021
- Govt to Build R&D Data Utilization Platform at AMED
June 3, 2021
- Nonpartisan Lawmakers’ Group Launched for Dementia Measures
June 2, 2021
- Japan Cabinet Hammers Out Strategy to Boost Vaccine Development
June 2, 2021
- Japan to Roll Out COVID-19 Vaccines at Workplaces from June 21
June 2, 2021
- Blue Letter Issued to OA Drug Joyclu after Anaphylaxis Reports
June 2, 2021
- Manufacturing and Use of Cannabis-Derived Drugs Should Be Permitted: MHLW Panel
June 2, 2021
- Eisai’s EZH2 Inhibitor, 3 More New Drugs Clear Key Panel, June OK Likely
May 31, 2021
- Panel OK’s Pfizer Vaccine Use in Age 12-Plus, Longer Refrigerator Storage
May 31, 2021
- Olumiant Added to MHLW’s COVID-19 Guide as Approved Drug
May 28, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…